Icosavax announced positive interim data from its early-stage study of IVX-A12 for a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine in older adults. Shares of the company surged almost 25% following the news.
Icosavax shares went up 23.7% year to date against the industry’s 6.2% decline.
ICVX specializes in vaccine development using an innovative technology called virus-like particles (VLP). The phase I study is focused on evaluating the safety and effectiveness of IVX-A12 at different dosage levels and ratios of vaccine components.
The candidate is a combination vaccine, made up of IVX-121 and IVX-241, targeting RSV and hMPV, respectively.
The initial findings from the phase I study demonstrated robust immune responses in older adults, lasting up to 28 days post vaccination. The study involved 140 healthy individuals aged between 60 and 75 years.
IVX-A12 was well tolerated by all dosage groups, with only mild or moderate adverse events reported. The candidate received a Fast Track designation from the FDA in February 2023.
Previous studies showed that using prefusion F antigens, a specific type of protein, for RSV vaccines can offer significant protection against pneumonia. Icosavax believes that its VLP technology, combined with the prefusion F antigens for both hMPV and RSV, could provide substantial protection against the leading causes of the disease.
Based on the promising interim results, ICVX is determined to advance IVX-A12 quickly. The company plans to move into a phase II study in mid-2023, specifically focusing on older adults. It also intends to conduct a human challenge clinical study to further evaluate the preventive capabilities of IVX-A12 against hMPV.
By leveraging its innovative VLP technology, Icosavax aims to develop a pan-respiratory vaccine that offers comprehensive protection against these life-threatening illnesses.
The company also announced a $67.8 million direct offering of common stock. The offering involves buying ICVX shares at $8.10 per unit and is expected to close by May 25, 2023.
The company has other developmental candidates for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zacks Rank and Stocks to Consider
Currently, Icosavax carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector are ADMA Biologics (ADMA - Free Report) , Allogene Therapeutics (ALLO - Free Report) and Omega Therapeutics (OMGA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Loss per estimates for ADMA have narrowed from 19 cents to 9 cents for 2023 in the past 60 days. Shares of ADMA have risen 3.6% in the year-to-date period.
ADMA Biologics’ earnings beat estimates in three of the trailing four quarters and met the mark in one, delivering an average surprise of 19.3%.
Loss per share estimates for Allogene have narrowed from $2.45 to $2.32 for 2023 and from $2.48 to $2.21 for 2024 in the past 60 days. Shares of ALLO have declined 3.8% in the year-to-date period.
Allogene’s earnings beat estimates in three of the last four quarters and missed the mark in one, the average surprise being 5.08%.
Loss per share estimates for Omega have narrowed from $2.51 to $2.18 for 2023 and from $2.57 to $2.22 for 2024 in the past 60 days. Shares of OMGA have surged 69.1% year to date.
Omega’s earnings outpaced estimates in two of the last four quarters, missed the mark in one, and met in another, delivering an average surprise of 8.24%.
Highest Returns for Any Asset Class
It’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.
Hurry, Download Special Report – It’s FREE >>
Icosavax announced positive interim data from its early-stage study of IVX-A12 for a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine in older adults. Shares of the company surged almost 25% following the news.
Icosavax shares went up 23.7% year to date against the industry’s 6.2% decline.
ICVX specializes in vaccine development using an innovative technology called virus-like particles (VLP). The phase I study is focused on evaluating the safety and effectiveness of IVX-A12 at different dosage levels and ratios of vaccine components.
The candidate is a combination vaccine, made up of IVX-121 and IVX-241, targeting RSV and hMPV, respectively.
The initial findings from the phase I study demonstrated robust immune responses in older adults, lasting up to 28 days post vaccination. The study involved 140 healthy individuals aged between 60 and 75 years.
IVX-A12 was well tolerated by all dosage groups, with only mild or moderate adverse events reported. The candidate received a Fast Track designation from the FDA in February 2023.
Previous studies showed that using prefusion F antigens, a specific type of protein, for RSV vaccines can offer significant protection against pneumonia. Icosavax believes that its VLP technology, combined with the prefusion F antigens for both hMPV and RSV, could provide substantial protection against the leading causes of the disease.
Based on the promising interim results, ICVX is determined to advance IVX-A12 quickly. The company plans to move into a phase II study in mid-2023, specifically focusing on older adults. It also intends to conduct a human challenge clinical study to further evaluate the preventive capabilities of IVX-A12 against hMPV.
By leveraging its innovative VLP technology, Icosavax aims to develop a pan-respiratory vaccine that offers comprehensive protection against these life-threatening illnesses.
The company also announced a $67.8 million direct offering of common stock. The offering involves buying ICVX shares at $8.10 per unit and is expected to close by May 25, 2023.
The company has other developmental candidates for influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Zacks Rank and Stocks to Consider
Currently, Icosavax carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector are ADMA Biologics (ADMA - Free Report) , Allogene Therapeutics (ALLO - Free Report) and Omega Therapeutics (OMGA - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Loss per estimates for ADMA have narrowed from 19 cents to 9 cents for 2023 in the past 60 days. Shares of ADMA have risen 3.6% in the year-to-date period.
ADMA Biologics’ earnings beat estimates in three of the trailing four quarters and met the mark in one, delivering an average surprise of 19.3%.
Loss per share estimates for Allogene have narrowed from $2.45 to $2.32 for 2023 and from $2.48 to $2.21 for 2024 in the past 60 days. Shares of ALLO have declined 3.8% in the year-to-date period.
Allogene’s earnings beat estimates in three of the last four quarters and missed the mark in one, the average surprise being 5.08%.
Loss per share estimates for Omega have narrowed from $2.51 to $2.18 for 2023 and from $2.57 to $2.22 for 2024 in the past 60 days. Shares of OMGA have surged 69.1% year to date.
Omega’s earnings outpaced estimates in two of the last four quarters, missed the mark in one, and met in another, delivering an average surprise of 8.24%.
Highest Returns for Any Asset Class
It’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.
No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.
Hurry, Download Special Report – It’s FREE >>
Get the latest research report on ADMA - FREE
Get the latest research report on ALLO - FREE
Get the latest research report on OMGA - FREE